logo

MLYS

Mineralys·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

MLYS fundamentals

Mineralys (MLYS) released its earnings on Nov 10, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.52 (YoY +53.98%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.52
+53.98%
Report date
Nov 10, 2025
MLYS Earnings Call Summary for Q3,2025
  • FDA-Backed NDA Submission: Confident in data for late 2025/early 2026 filing after positive pre-NDA feedback.
  • Clinical Efficacy Across Populations: 9-14mmHg BP reduction in diverse, high-risk patients, including 50% Black/African-American in key trial.
  • Financial Strength: $593M cash; reduced R&D expenses offset by G&A growth, improving net loss to $36.9M.
EPS
Revenue

Revenue & Expenses

Key Indicators

Mineralys (MLYS) key financial stats and ratios, covering profitability, financial health, and leverage.
Mineralys (MLYS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Mineralys (MLYS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Mineralys (MLYS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Mineralys (MLYS) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Mineralys (MLYS) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield